Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trinity Biotech (TRIBY) -- Ignore unavailable to you. Want to Upgrade?

To: Hope who wrote (11241)	12/8/1998 8:45:00 AM
From: Ron Luhmann	Respond to of 14328

you're much too polite and very pc Hope :-) ... just found out the Sec of Def will visit my ship for Xmas :-( ...ugh! so instead of being against the pier for a few days...enjoying some wine or a cold one on Christmas in the Gulf we will be underway!! :-( thanks alot jerk !! CNN press hound a stocking stuffer!! ... SGII will sign a Major deal with Mitsubishi this week should see large press release next week...already starting to move Merry Christmas!!

To: Hope who wrote (11241)	12/8/1998 8:49:00 AM
From: AgAuUSA	Read Replies (1) \| Respond to of 14328

TITLE: Home collection kits for HIV testing: evaluation of three strategies for dealing with insufficient dried blood specimens. AUTHORS: Tao G; Kassler WJ; Branson BM; Peterman TA AUTHOR AFFILIATION: Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, U.S.A. SOURCE: J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Aug 1;15(4):312-7. SECONDARY SOURCE ID: MED/97436619 ABSTRACT: Home collection kits allow individuals to obtain a blood specimen at home and send it to a laboratory for HIV testing. In preliminary studies, 15% of kit users submitted specimens considered to be insufficient for analysis. The current Public Health Service policy requires the laboratory to reject all such specimens entirely and request a second specimen, even though some specimens are sufficient to perform an enzyme immunoassay (EIA) but not a Western blot (WB) test. Using decision analysis, we evaluated three strategies to handle specimens sufficient to perform an EIA but insufficient to perform a WB analysis: current recommendation, or baseline, for which no test is preformed and "quantity not sufficient" is reported; alternative 1 , for which an EIA is done and reported as "negative" or "quantity not sufficient" (if initially reactive); and alternative 2, for which an EIA is done and reported as "negative" or "a reactive screening test" (if initially reactive). Baseline strategy requires all consumers with an initial specimen sufficient for EIA only to submit a second specimen, but either alternative requires fewer than 3% to submit a second specimen. Although 80% of consumers with an initial specimen sufficient for EIA learn their test results only with the baseline strategy, more than 99% learn their test results with either alternative. With the scenario of high (2%) HIV prevalence, 91% of consumers who would be told "reactive screening test" are truly infected. At a low (0.1%) HIV prevalence, 33% of consumers who would be told "reactive screening test" are truly infected. When a specimen is sufficient for EIA only, it is preferable to perform the EIA instead of rejecting the specimen, because many persons can get results from the initial specimen and because many fewer are required to submit a second specimen. Current policy should be reexamined in light of these findings. MAIN MESH HEADINGS: Blood Specimen Collection HIV Infections/DIAGNOSIS *Reagent Kits, Diagnostic ADDITIONAL MESH HEADINGS: Human Immunoenzyme Techniques PUBLICATION TYPES: JOURNAL ARTICLE LANGUAGES: Eng